[Video] TIDES: AZD9150 and its Effect on Tumors

In today's featured interview from TIDES 2014, David C. Blakey, Ph.D., the Chief Scientist of Oncology iMED at AstraZeneca discusses the next generation of antisense molecules, AZD9150 and its effect on tumors and why TIDES is a great place to be for the industry. He also talks about bigger traction, which tackle lower uptake tissues and a combination of both peptides and nucleotides. To learn more, watch this interview:



This year at TIDES 2015, AstraZeneca's Regina Fritsche-Danielson, Ph.D., Associate Professor and Senior Director and Head of Bioscience Heart Failure Department will present Modified mRNA as a Potential Therapeutic for Patients with Cardiovascular Disease.  For more information on this session and the rest of the program, download the agenda.  As a reader of this blog, when you register to join us and mention code XB15180BLOG, you can save 20% off the standard rate.

Share this article with your social network, just click below to share now!

Share |